vs
Side-by-side financial comparison of Bio-Techne (TECH) and UNISYS CORP (UIS). Click either name above to swap in a different company.
UNISYS CORP is the larger business by last-quarter revenue ($574.5M vs $295.9M, roughly 1.9× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs 3.3%, a 9.6% gap on every dollar of revenue. On growth, UNISYS CORP posted the faster year-over-year revenue change (5.3% vs -6.4%). Over the past eight quarters, UNISYS CORP's revenue compounded faster (8.5% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Unisys Corporation is a technology company founded in 1986 and headquartered in Blue Bell, Pennsylvania. The company provides cloud, AI, digital workplace, logistics, and enterprise computing services.
TECH vs UIS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $574.5M |
| Net Profit | $38.0M | $18.7M |
| Gross Margin | 64.6% | 33.9% |
| Operating Margin | 18.4% | 13.3% |
| Net Margin | 12.8% | 3.3% |
| Revenue YoY | -6.4% | 5.3% |
| Net Profit YoY | 68.3% | -37.7% |
| EPS (diluted) | $0.24 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $295.9M | $574.5M | ||
| Q3 25 | — | $460.2M | ||
| Q2 25 | $317.0M | $483.3M | ||
| Q1 25 | $316.2M | $432.1M | ||
| Q4 24 | $297.0M | $545.4M | ||
| Q3 24 | $289.5M | $497.0M | ||
| Q2 24 | $306.1M | $478.2M | ||
| Q1 24 | $303.4M | $487.8M |
| Q4 25 | $38.0M | $18.7M | ||
| Q3 25 | — | $-308.9M | ||
| Q2 25 | $-17.7M | $-20.1M | ||
| Q1 25 | $22.6M | $-29.5M | ||
| Q4 24 | $34.9M | $30.0M | ||
| Q3 24 | $33.6M | $-61.9M | ||
| Q2 24 | $40.6M | $-12.0M | ||
| Q1 24 | $49.1M | $-149.5M |
| Q4 25 | 64.6% | 33.9% | ||
| Q3 25 | — | 25.5% | ||
| Q2 25 | 62.7% | 26.9% | ||
| Q1 25 | 67.9% | 24.9% | ||
| Q4 24 | 65.3% | 32.1% | ||
| Q3 24 | 63.2% | 29.2% | ||
| Q2 24 | 66.4% | 27.2% | ||
| Q1 24 | 67.4% | 27.9% |
| Q4 25 | 18.4% | 13.3% | ||
| Q3 25 | — | -7.3% | ||
| Q2 25 | -7.5% | 6.3% | ||
| Q1 25 | 12.2% | 1.2% | ||
| Q4 24 | 16.0% | 8.9% | ||
| Q3 24 | 13.8% | 1.5% | ||
| Q2 24 | 15.0% | 4.9% | ||
| Q1 24 | 22.1% | 3.6% |
| Q4 25 | 12.8% | 3.3% | ||
| Q3 25 | — | -67.1% | ||
| Q2 25 | -5.6% | -4.2% | ||
| Q1 25 | 7.1% | -6.8% | ||
| Q4 24 | 11.7% | 5.5% | ||
| Q3 24 | 11.6% | -12.5% | ||
| Q2 24 | 13.3% | -2.5% | ||
| Q1 24 | 16.2% | -30.6% |
| Q4 25 | $0.24 | $0.24 | ||
| Q3 25 | — | $-4.33 | ||
| Q2 25 | $-0.11 | $-0.28 | ||
| Q1 25 | $0.14 | $-0.42 | ||
| Q4 24 | $0.22 | $0.45 | ||
| Q3 24 | $0.21 | $-0.89 | ||
| Q2 24 | $0.26 | $-0.17 | ||
| Q1 24 | $0.31 | $-2.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $413.9M |
| Total DebtLower is stronger | $260.0M | $729.0M |
| Stockholders' EquityBook value | $2.0B | $-282.6M |
| Total Assets | $2.5B | $1.8B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.9M | $413.9M | ||
| Q3 25 | — | $321.9M | ||
| Q2 25 | $162.2M | $300.8M | ||
| Q1 25 | $140.7M | $393.1M | ||
| Q4 24 | $177.5M | $376.5M | ||
| Q3 24 | $187.5M | $373.7M | ||
| Q2 24 | $152.9M | $344.9M | ||
| Q1 24 | $145.3M | $382.8M |
| Q4 25 | $260.0M | $729.0M | ||
| Q3 25 | — | $723.2M | ||
| Q2 25 | $346.0M | $692.7M | ||
| Q1 25 | $330.0M | $488.3M | ||
| Q4 24 | $300.0M | $488.2M | ||
| Q3 24 | $300.0M | $488.5M | ||
| Q2 24 | $319.0M | $489.2M | ||
| Q1 24 | $389.0M | $488.4M |
| Q4 25 | $2.0B | $-282.6M | ||
| Q3 25 | — | $-300.2M | ||
| Q2 25 | $1.9B | $-221.5M | ||
| Q1 25 | $2.0B | $-267.8M | ||
| Q4 24 | $2.1B | $-283.4M | ||
| Q3 24 | $2.1B | $-202.2M | ||
| Q2 24 | $2.1B | $-174.1M | ||
| Q1 24 | $2.0B | $-158.6M |
| Q4 25 | $2.5B | $1.8B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $2.6B | $1.8B | ||
| Q1 25 | $2.6B | $1.8B | ||
| Q4 24 | $2.7B | $1.9B | ||
| Q3 24 | $2.7B | $1.9B | ||
| Q2 24 | $2.7B | $1.9B | ||
| Q1 24 | $2.7B | $1.9B |
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $104.9M |
| Free Cash FlowOCF − Capex | — | $97.3M |
| FCF MarginFCF / Revenue | — | 16.9% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | — | 5.61× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-170.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $104.9M | ||
| Q3 25 | — | $38.0M | ||
| Q2 25 | $98.2M | $-316.2M | ||
| Q1 25 | $41.1M | $33.3M | ||
| Q4 24 | $84.3M | $76.6M | ||
| Q3 24 | $63.9M | $32.0M | ||
| Q2 24 | $75.5M | $2.7M | ||
| Q1 24 | $81.0M | $23.8M |
| Q4 25 | — | $97.3M | ||
| Q3 25 | — | $32.4M | ||
| Q2 25 | $93.3M | $-324.1M | ||
| Q1 25 | $31.0M | $24.4M | ||
| Q4 24 | $77.5M | $66.5M | ||
| Q3 24 | $54.7M | $25.2M | ||
| Q2 24 | $57.5M | $-6.0M | ||
| Q1 24 | $64.5M | $17.1M |
| Q4 25 | — | 16.9% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | 29.4% | -67.1% | ||
| Q1 25 | 9.8% | 5.6% | ||
| Q4 24 | 26.1% | 12.2% | ||
| Q3 24 | 18.9% | 5.1% | ||
| Q2 24 | 18.8% | -1.3% | ||
| Q1 24 | 21.3% | 3.5% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 1.5% | 1.6% | ||
| Q1 25 | 3.2% | 2.1% | ||
| Q4 24 | 2.3% | 1.9% | ||
| Q3 24 | 3.2% | 1.4% | ||
| Q2 24 | 5.9% | 1.8% | ||
| Q1 24 | 5.4% | 1.4% |
| Q4 25 | — | 5.61× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 2.42× | 2.55× | ||
| Q3 24 | 1.90× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
UIS
Segment breakdown not available.
